Plain-English translation of NCT05895136 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a combination of two medications — and — can safely help people with decompensated cirrhosis (severe liver disease) recover better after they leave the hospital. Some participants will receive the medication along with their standard liver care, while others will receive only their standard care. The researchers want to know if this new treatment combination is safe, effective, and whether it's worth the cost.
People with severe liver cirrhosis who are hospitalized often have serious complications when they go home, and many have poor outcomes. This medication combination may help protect the liver and prevent these complications, but it hasn't been fully tested yet in this patient group.
You likely qualify if…
You likely don't qualify if…
After you're ready to leave the hospital, you'll be randomly assigned to either receive the new medication combination or standard care alone. You'll attend study visits where doctors will perform blood tests and other assessments to monitor your liver disease and how you're doing. The study will track your health over time to see if the medication helps you stay healthier and avoid complications.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
France
Germany
Italy